Pharmaceuticals & Biotechnology
Valuation | |
|---|---|
| Market Cap | 1.01 LCr |
| Price/Earnings (Trailing) | 21.84 |
| Price/Sales (Trailing) | 3.83 |
| EV/EBITDA | 14 |
| Price/Free Cashflow | -71.15 |
| MarketCap/EBT | 17.38 |
| Enterprise Value | 1.06 LCr |
Fundamentals | |
|---|---|
Growth & Returns | |
|---|---|
| Price Change 1W | 1.1% |
| Price Change 1M | 2.1% |
| Price Change 6M | 14.5% |
| Price Change 1Y | 12.8% |
| 3Y Cumulative Return | 49.1% |
| 5Y Cumulative Return | 15.9% |
| 7Y Cumulative Return | 16.3% |
| 10Y Cumulative Return | 2.2% |
| Revenue (TTM) |
| 26.49 kCr |
| Rev. Growth (Yr) | 25.1% |
| Earnings (TTM) | 4.67 kCr |
| Earnings Growth (Yr) | 37.5% |
Profitability | |
|---|---|
| Operating Margin | 24% |
| EBT Margin | 22% |
| Return on Equity | 23.67% |
| Return on Assets | 13.94% |
| Free Cashflow Yield | -1.41% |
| Cash Flow from Investing (TTM) | -1.6 kCr |
| Cash Flow from Operations (TTM) | 429.94 Cr |
| Cash Flow from Financing (TTM) | 1.73 kCr |
| Cash & Equivalents | 1.33 kCr |
| Free Cash Flow (TTM) | -1.25 kCr |
| Free Cash Flow/Share (TTM) | -27.42 |
Balance Sheet | |
|---|---|
| Total Assets | 33.5 kCr |
| Total Liabilities | 13.77 kCr |
| Shareholder Equity | 19.73 kCr |
| Current Assets | 20.27 kCr |
| Current Liabilities | 10.82 kCr |
| Net PPE | 5.26 kCr |
| Inventory | 5.95 kCr |
| Goodwill | 2.47 kCr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.17 |
| Debt/Equity | 0.29 |
| Interest Coverage | 13.48 |
| Interest/Cashflow Ops | 2.35 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 12 |
| Dividend Yield | 0.55% |
| Shares Dilution (1Y) | 0.10% |
| Shares Dilution (3Y) | 0.40% |
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Growth: Awesome revenue growth! Revenue grew 19.4% over last year and 64% in last three years on TTM basis.
Past Returns: Outperforming stock! In past three years, the stock has provided 49.1% return compared to 12.4% by NIFTY 50.
Profitability: Very strong Profitability. One year profit margin are 18%.
Smart Money: Smart money has been increasing their position in the stock.
Balance Sheet: Strong Balance Sheet.
Size: It is among the top 200 market size companies of india.
No major cons observed.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Growth: Awesome revenue growth! Revenue grew 19.4% over last year and 64% in last three years on TTM basis.
Past Returns: Outperforming stock! In past three years, the stock has provided 49.1% return compared to 12.4% by NIFTY 50.
Profitability: Very strong Profitability. One year profit margin are 18%.
Smart Money: Smart money has been increasing their position in the stock.
Balance Sheet: Strong Balance Sheet.
Size: It is among the top 200 market size companies of india.
No major cons observed.
Investor Care | |
|---|---|
| Dividend Yield | 0.55% |
| Dividend/Share (TTM) | 12 |
| Shares Dilution (1Y) | 0.10% |
| Earnings/Share (TTM) | 101.73 |
Financial Health | |
|---|---|
| Current Ratio | 1.87 |
| Debt/Equity | 0.29 |
Technical Indicators | |
|---|---|
| RSI (14d) | 61.76 |
| RSI (5d) | 76.02 |
| RSI (21d) | 50.46 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Buy |
| RSI Signal | Hold |
| RSI5 Signal | Sell |
| RSI21 Signal | Hold |
| SMA 5 Signal | Sell |
| SMA 10 Signal |
Updated May 4, 2025
Lupin Limited has received US FDA approval for its Tolvaptan tablets, marking a significant step into the nephrology market.
The approval for Tolvaptan is expected to generate $200 million in annual revenue by FY26, highlighting a strong market potential.
Lupin Diagnostics achieved 100% NABL accreditation across all its labs, showcasing its commitment to quality patient care.
Summary of Lupin's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
In the Q2 FY2026 earnings call, management expressed a highly optimistic outlook for Lupin Limited, highlighting a record performance with total revenue from operations exceeding INR 7,048 crores and EBITDA surpassing INR 2,138 crores. The EBITDA margin expanded to 31.3%, reflecting a 750 basis points YoY improvement. Management noted this quarter represents the 13th consecutive quarter of year-over-year growth, with significant contributions from the U.S. market where sales grew by 47% YoY.
Key forward-looking points include:
U.S. Market Growth: The U.S. business is expected to maintain momentum, with an anticipated revenue of USD 275 million to USD 300 million per quarter post-regulatory exclusivity for Tolvaptan. Management targets to sustain over USD 1 billion annual revenue for FY27.
New Product Launches: Upcoming launches include Risperdal Consta® and Pegfilgrastim. The plan includes securing approvals for several complex injectable products and expanding biosimilars in the U.S. market, aiming to have five products by FY30.
India Business Performance: Management confidently expects domestic growth to outperform the Indian Pharmaceutical Market (IPM) by 1.2 to 1.3 times, with over 80 new product launches planned.
Acquisition Impact: The planned acquisition of VISUfarma is expected to enhance margins and growth, aiming for a global specialty business to reach USD 150 million in revenue next year.
Capital Allocation: Lupin plans to invest in expanding its specialty portfolio, with a significant allocation of INR 250 million aimed at enhancing production capacity for respiratory products in the U.S.
R&D Focus: The R&D spending is projected at 7.5% of sales, with an increased focus on complex and specialty drugs, alongside strengthening the innovation pipeline.
Management maintains a disciplined approach while advancing in financial growth, reinforcing a long-term vision toward sustainability and patient trust in the healthcare space.
Understand Lupin ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| Lupin Investments Private Limited | 45.36% |
| Hdfc Trustee Company Ltd. A/C Hdfc Balanced Advantage Fund | 4.59% |
| Nippon Life India Trustee Ltd- A/C Nippon India Growth Mid Cap Fund | 2.85% |
| Icici Prudential Value Fund | 2.46% |
| Nps Trust- A/C Hdfc Pension Fund Management Limited Scheme E - Tier I | 1.94% |
| Mirae Asset Large & Midcap Fund | 1.92% |
Detailed comparison of Lupin against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries | 4.08 LCr | 58.94 kCr | +1.90% | 0.00% | 37.37 | 6.92 | - | - |
| DIVISLAB | Divi's Lab | 1.63 LCr | 10.75 kCr |
Comprehensive comparison against sector averages
LUPIN metrics compared to Pharmaceuticals
| Category | LUPIN | Pharmaceuticals |
|---|---|---|
| PE | 21.62 | 33.87 |
| PS | 3.79 | 4.67 |
| Growth | 19.4 % | 10.8 % |
Lupin is a pharmaceutical company with stock ticker LUPIN and a market capitalization of Rs. 96,055.7 Crores. Operating both in India and internationally, Lupin Limited, along with its subsidiaries, is engaged in various aspects of the pharmaceutical business, including drug discovery, development, production, marketing, and sale of both branded and generic formulations, biosimilars, over-the-counter and specialty drugs, as well as active pharmaceutical ingredients (APIs).
The company's extensive portfolio includes formulations targeting a wide range of therapeutic areas such as:
Additionally, Lupin engages in bio clinical research and operates through a network of labs, LupiMitra collection centers, and pick-up points.
Founded in 1968 and headquartered in Mumbai, India, the company was previously known as Lupin Chemicals Limited, adopting its current name in 2001.
Lupin reported a trailing 12 months revenue of Rs. 22,194.6 Crores and has a profitable standing, earning Rs. 2,892.1 crores in profit over the last four quarters. Over the past three years, the company has achieved a revenue growth of 34.5%.
The company also rewards its investors with dividends, providing a dividend yield of 0.38% per year, and distributed Rs. 8 as dividend per share in the last 12 months. However, it has diluted shareholders' stakes by 0.4% over the past three years.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
| Buy |
| SMA 20 Signal | Buy |
| SMA 50 Signal | Buy |
| SMA 100 Signal | Buy |
LUPIN vs Pharmaceuticals (2021 - 2026)
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
This information is AI-generated and may contain inaccuracies. Please verify from multiple sources.
Kunal Dhamesha: "How do we see this USD 315 million number moving in the coming quarters? What are the key launches in FY26 and FY27?"
Vinita Gupta: "We anticipate a decrease to USD 275-300 million quarterly due to market erosion from upcoming competition. However, we are optimistic about sustaining a USD 1 billion annual figure. Upcoming launches include Risperdal Consta® and Pegfilgrastim, with plans for several biosimilars and injectables ramping up."
Kunal Dhamesha: "What should we look forward to regarding EBITDA margin guidance for FY27?"
Ramesh Swaminathan: "We expect a reduction in margins in H2 FY26 but aim to maintain FY27 margins around 24%-25%, despite increasing R&D expenditures. Growth opportunities in India could support these margins."
Kunal Dhamesha: "Have we submitted a response to the inspection findings at the Nagpur facility, and how crucial is this facility for future growth?"
Nilesh Gupta: "Yes, we've submitted our response to the recent audit. While we're not satisfied with the observations, we believe they're addressable. The facility is vital for our injectable and biotech products, and we're committed to its compliance."
Bino Pathiparampil: "Could you compare Q2 revenue of Tolvaptan QoQ and confirm if Mirabegron is maintaining its growth rate?"
Vinita Gupta: "While we don't provide specific product guidance, Tolvaptan significantly contributed to Q2. Mirabegron has also shown growth QoQ, maintaining a strong performance."
Shyam Srinivasan: "Can you explain the strategic rationale behind the VISUfarma acquisition?"
Vinita Gupta: "The acquisition broadens our European presence, adding key markets in Italy and Spain. It strengthens our ophthalmology franchise, allowing us to leverage a portfolio for more diverse product launches across Europe."
Saion Mukherjee: "What's driving remarkable growth in emerging markets like Brazil and South Africa, and is this sustainable?"
Vinita Gupta: "We see growth opportunities in Europe and Latin America, expecting to sustain double-digit growth driven by strong product launches, particularly in our diabetes franchise in Brazil."
Neha Manpuria: "How should we view gross margins for the full year based on current quarterly performance?"
Ramesh Swaminathan: "Current margins are impacted by specific products, including Tolvaptan. While future slight declines may occur, we anticipate an EBITDA margin of about 24%-25%, balancing gross margin adjustments with operating leverage."
Vishal Manchanda: "Can you quantify annual spending on biosimilar development? Are we currently burning money in this area?"
Vinita Gupta: "Yes, we're investing significantly into biosimilars. The burn is manageable, especially considering partnerships for many products, enabling us to remain positive in future years regarding profitability."
| Sbi Elss Tax Saver Fund | 1.85% |
| Life Insurance Corporation Of India - P & Gs Fund | 1.81% |
| Hdfc Life Insurance Company Limited | 1.3% |
| Manju D Gupta | 0.85% |
| Nilesh Gupta | 0.2% |
| Anuja Gupta | 0.16% |
| D B Gupta HUF (Nilesh Deshbandhu Gupta, Karta of HUF) | 0.14% |
| Vinita Gupta | 0.07% |
| Richa Gupta | 0.05% |
| Kavita Gupta | 0.04% |
| Veda Nilesh Gupta | 0.02% |
| Neel Deshbandhu Gupta | 0.01% |
| Manju D Gupta (As a Trustee of Gupta Family Trust) | 0% |
| Shefali Nath Gupta | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
| -1.40% |
| +5.20% |
| 65.86 |
| 15.18 |
| - |
| - |
| TORNTPHARM | Torrent Pharmaceuticals | 1.38 LCr | 12.65 kCr | +6.00% | +41.40% | 60.76 | 10.91 | - | - |
| CIPLA | Cipla | 1.09 LCr | 29.37 kCr | -3.00% | -7.20% | 24.07 | 3.73 | - | - |
| DRREDDY | Dr. Reddy's Lab | 1.06 LCr | 36.09 kCr | +8.00% | +6.00% | 18.98 | 2.94 | - | - |
| AUROPHARMA | Aurobindo Pharma | 68.8 kCr | 33.73 kCr | +1.00% | +4.70% | 19.73 | 2.04 | - | - |
Press Release / Media Release • 16 Feb 2026 Lupin Signs License and Supply Agreement with Spektus to Commercialize Novel Antidepressant DeslaFlex in Canada. |
Newspaper Publication • 14 Feb 2026 Copy of Newspaper Publication in respect of Unaudited Financial Results of the Company for quarter and nine months ended December 31, 2025. |
Analyst / Investor Meet • 13 Feb 2026 Link of Audio recording of the Earnings Call-Q3 FY26 |
Allotment of ESOP / ESPS • 13 Feb 2026 Intimation of allotment of 75273 equity shares under ESOP. |
Press Release / Media Release • 13 Feb 2026 Anand Kripalu Joins Lupin Board as Independent Director. |
Investor Presentation • 12 Feb 2026 The Company has informed the Exchange about Investor Presentation on the Unaudited Financial Results for the quarter and nine months ended December 31, 2025. |
Press Release / Media Release • 12 Feb 2026 Lupin Q3 FY2026 Results |
| 4% |
| 5,334 |
| 5,131 |
| 4,932 |
| 4,828 |
| 4,750 |
| 4,660 |
| Profit Before exceptional items and Tax | -2.9% | 1,949 | 2,007 | 1,416 | 896 | 1,071 | 1,055 |
| Exceptional items before tax | - | -426.57 | 0 | 0 | 0 | 0 | 0 |
| Total profit before tax | -24.2% | 1,522 | 2,007 | 1,416 | 896 | 1,071 | 1,055 |
| Current tax | -36.8% | 205 | 324 | 491 | 281 | 269 | 203 |
| Deferred tax | -31% | 137 | 198 | -296.81 | -167.65 | -56.69 | -7.55 |
| Total tax | -34.5% | 342 | 522 | 194 | 113 | 212 | 195 |
| Total profit (loss) for period | -20.5% | 1,181 | 1,485 | 1,221 | 782 | 859 | 859 |
| Other comp. income net of taxes | 25.3% | 120 | 96 | 160 | 23 | -119.53 | 58 |
| Total Comprehensive Income | -17.7% | 1,301 | 1,581 | 1,382 | 805 | 739 | 917 |
| Earnings Per Share, Basic | -21.1% | 25.74 | 32.36 | 26.7 | 16.93 | 18.75 | 18.7 |
| Earnings Per Share, Diluted | -21.1% | 25.67 | 32.28 | 26.62 | 16.87 | 18.69 | 18.64 |
| 10.3% |
| 2,312 |
| 2,096 |
| 1,934 |
| 1,918 |
| 1,696 |
| 1,703 |
| Finance costs | 50.9% | 84 | 56 | 98 | 73 | 41 | 53 |
| Depreciation and Amortization | -10.6% | 648 | 725 | 548 | 514 | 503 | 519 |
| Other expenses | 4.2% | 4,258 | 4,087 | 3,444 | 5,111 | 3,134 | 3,208 |
| Total Expenses | 2% | 12,227 | 11,989 | 10,823 | 12,084 | 9,555 | 9,689 |
| Profit Before exceptional items and Tax | 76.5% | 4,914 | 2,785 | 527 | -161.53 | 1,630 | 1,811 |
| Exceptional items before tax | - | -77.22 | 0 | 0 | 0 | 0 | -759.21 |
| Total profit before tax | 73.7% | 4,837 | 2,785 | 527 | -161.53 | 1,630 | 1,052 |
| Current tax | 77.2% | 857 | 484 | 96 | 58 | 363 | 362 |
| Deferred tax | 122.8% | 7.04 | -25.45 | 6.04 | -30.63 | 8.23 | -37.35 |
| Total tax | 88.4% | 864 | 459 | 102 | 27 | 371 | 325 |
| Total profit (loss) for period | 70.8% | 3,973 | 2,326 | 425 | -188.7 | 1,259 | 728 |
| Other comp. income net of taxes | -171.9% | -14.47 | -4.69 | -23.92 | 1.03 | 45 | -69.25 |
| Total Comprehensive Income | 70.6% | 3,958 | 2,321 | 401 | -187.67 | 1,303 | 658 |
| Earnings Per Share, Basic | 71.9% | 87.1 | 51.1 | 9.35 | -4.16 | 27.77 | 16.07 |
| Earnings Per Share, Diluted | 72% | 86.79 | 50.87 | 9.31 | -4.16 | 27.65 | 15.99 |
| 39% |
| 322 |
| 232 |
| 436 |
| 411 |
| 471 |
| 738 |
| Goodwill | - | 0 | 0 | 16 | 16 | 16 | 16 |
| Non-current investments | 0% | 10,951 | 10,951 | 10,916 | 10,772 | 9,740 | 9,535 |
| Loans, non-current | 0% | 128 | 128 | 23 | 3.57 | 3.6 | 4.04 |
| Total non-current financial assets | -0.2% | 11,137 | 11,154 | 10,994 | 10,879 | 9,846 | 9,629 |
| Total non-current assets | 0.1% | 16,553 | 16,537 | 15,727 | 15,635 | 15,054 | 15,113 |
| Total assets | 14.9% | 32,661 | 28,432 | 26,471 | 24,923 | 23,497 | 22,684 |
| Borrowings, non-current | -100.4% | 0 | 226 | 0 | 0 | 0 | 0 |
| Total non-current financial liabilities | 27.1% | 287 | 226 | 141 | 86 | 78 | 94 |
| Provisions, non-current | 5.5% | 420 | 398 | 371 | 330 | 358 | 316 |
| Total non-current liabilities | 20.3% | 1,027 | 854 | 741 | 626 | 689 | 644 |
| Borrowings, current | - | 706 | 0 | 526 | 18 | 21 | 613 |
| Total current financial liabilities | 43.2% | 3,318 | 2,317 | 2,899 | 2,426 | 2,282 | 2,507 |
| Provisions, current | -1.7% | 176 | 179 | 90 | 495 | 483 | 489 |
| Current tax liabilities | 61.3% | 556 | 345 | 416 | 353 | 385 | 323 |
| Total current liabilities | 36.4% | 4,409 | 3,233 | 3,752 | 3,646 | 3,481 | 3,628 |
| Total liabilities | 30.9% | 5,437 | 4,154 | 4,493 | 4,320 | 4,220 | 4,272 |
| Equity share capital | 0% | 91 | 91 | 91 | 91 | 91 | 91 |
| Total equity | 12.1% | 27,225 | 24,278 | 21,978 | 20,603 | 19,277 | 18,412 |
| Total equity and liabilities | 14.9% | 32,661 | 28,432 | 26,471 | 24,923 | 23,497 | 22,684 |
| 22.7% |
| 3,253 |
| 2,652 |
| 1,911 |
| 104 |
| - |
| - |
| Income taxes paid (refund) | 452.7% | 808 | 147 | 127 | -148.17 | - | - |
| Net Cashflows From Operating Activities | -2.4% | 2,445 | 2,505 | 1,785 | 252 | - | - |
| Cashflows used in obtaining control of subsidiaries | -68.4% | 413 | 1,303 | 1,102 | 0 | - | - |
| Proceeds from sales of PPE | 11.9% | 9.86 | 8.92 | 14 | 4.52 | - | - |
| Purchase of property, plant and equipment | 85.2% | 1,294 | 699 | 575 | 597 | - | - |
| Cash receipts from repayment of advances and loans made to other parties | - | 25 | 0 | 0 | 0 | - | - |
| Interest received | 1298.1% | 73 | 6.15 | 7.11 | 23 | - | - |
| Other inflows (outflows) of cash | 69.4% | -101.84 | -335.32 | 396 | 1,534 | - | - |
| Net Cashflows From Investing Activities | -10.4% | -1,766.32 | -1,599.8 | -1,259.73 | -472.93 | - | - |
| Proceeds from issuing shares | - | 40 | 0 | 0 | 0 | - | - |
| Proceeds from exercise of stock options | -107.1% | 0 | 15 | 1.94 | 16 | - | - |
| Proceeds from borrowings | - | 0 | 0 | 0 | 492 | - | - |
| Repayments of borrowings | -97.1% | 18 | 595 | 177 | 0.15 | - | - |
| Payments of lease liabilities | -8.2% | 68 | 74 | 68 | 59 | - | - |
| Dividends paid | 100% | 365 | 183 | 182 | 295 | - | - |
| Interest paid | 71.4% | 49 | 29 | 73 | 51 | - | - |
| Net Cashflows from Financing Activities | 46.9% | -460.23 | -867.07 | -498.26 | 102 | - | - |
| Net change in cash and cash eq. | 486.5% | 218 | 38 | 27 | -118.31 | - | - |
Analysis of Lupin's financial performance, highlighting revenue trends, growth patterns, and key metrics through quarterly analysis.
Last Updated: Dec 31, 2025
| Description | Share | Value |
|---|---|---|
| Pharmaceuticals | 100.0% | 7.1 kCr |
| Total | 7.1 kCr |